Details for Patent: 11,021,475

Which drugs does patent 11,021,475 protect, and when does it expire?

Patent 11,021,475 protects SOTYKTU and is included in one NDA.

This patent has seventy-one patent family members in thirty-nine countries.

Summary for Patent: 11,021,475

Title:	Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
Abstract:	Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.
Inventor(s):	Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski
Assignee:	Bristol Myers Squibb Co
Application Number:	US16/687,279
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Dosage form;

Drugs Protected by US Patent 11,021,475

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bristol	SOTYKTU	deucravacitinib	TABLET;ORAL	214958-001	Sep 9, 2022		RX	Yes	Yes	11,021,475					TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN ADULTS WHO ARE CANDIDATES FOR SYSTEMIC THERAPY OR PHOTOTHERAPY

International Family Members for US Patent 11,021,475

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2922846		301238	Netherlands
European Patent Office	2922846		CA 2023 00024	Denmark
European Patent Office	2922846		PA2023523	Lithuania